Inotiv's book value per share for the quarter that ended in Dec. 2023 was $9.86.
During the past 12 months, Inotiv's average Book Value Per Share Growth Rate was -10.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 147.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 85.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 27.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Inotiv was 147.30% per year. The lowest was -29.80% per year. And the median was -2.60% per year.
Inotiv's current price is $2.24. Its book value per share for the quarter that ended in Dec. 2023 was $9.86. Hence, today's PB Ratio of Inotiv is 0.23.
During the past 13 years, the highest P/B Ratio of Inotiv was 45.69. The lowest was 0.16. And the median was 1.78.
Inotiv Book Value per Share Historical Data
The historical data trend for Inotiv's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inotiv's Book Value per Share
For the Diagnostics & Research subindustry, Inotiv's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv's PB Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's PB Ratio distribution charts can be found below:
* The bar in red indicates where Inotiv's PB Ratio falls into.
Inotiv Book Value per Share Calculation
Inotiv's Book Value Per Share for the fiscal year that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Inotiv (NAS:NOTV) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Inotiv Book Value per Share Related Terms
Thank you for viewing the detailed overview of Inotiv's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NOTV has been successfully added to your 